Featured Trends
We’ve sliced and diced our portfolio into distinct “trends” that define our edge.
Climate 100
We are pleased to report that as of April 2021 the SOSV Climate Tech 100 have raised $1.85 billion from investors and have a market cap of $5.65 billion. The average company is four years old. SOSV (our parent fund) has invested $89 million in these companies and was in most cases the first investor, though we continued investing through early rounds.
IndieBio has never been one to shy away from the riskiest and most impactful investments for our planet. In fact, we embrace them.
Female Founder
Boosting female representation in the startup world is an ongoing challenge, but we’re dedicated to gender balance, not only because it’s the right thing to do, but because we would be dismissing impressive companies otherwise. We’ve found that more gender balance leads to better workplace culture and better ideas being exchanged.
Future of Food
It’s not just that we can make meat and fish in the lab, or with mushrooms and chickpeas. It’s not just that AI can predict the best plant ingredients to make the best tasting milk and yogurt. And it’s not just that yeast can be fermented to produce the healthier and better food preservatives. We’re diving deep every day into the foods that will satisfy novelty-seekers and conventionalists alike.
We’re putting big bets on the newest technologies and trends we think are ahead of the curve.
Future of Medicine
Medicine ain’t what it used to be. Today, bloodletting, skull-drilling and giving children cocaine for toothaches are relics of the past. Tomorrow, so too will addictive opioids, chemotherapy, and psychiatric drugs that are non-selectively bathing our bodies in chemicals.
The future of medicine is an exciting one, and we’re excited to share the most exciting technologies that enable the next wave of medicine and healthcare.
Impact
Our mission has always been Human and Planetary Health from the beginning, so it’s hard to say which of our companies are “impact” companies (in some ways, they all are).
Here, we narrowed down the startups that are directly addressing sustainability issues, improving public health, mitigating inequality, and democratizing access to infrastructure and technologies.
New Frontiers
Raising Now
Every season of the year, a new batch and about one-sixth of our alumni are in raise mode. These companies are currently raising and would love to talk to interested investors. We can set up those meetings or you can contact the companies directly.
Sustainable Solutions
In the U.S. alone we use 12 to 15 billion pounds of food packaging film annually, but less than 5% is recycled. Moreover, these plastic films contain PFAS (aka, “forever chemicals”) that leach into foods and have been linked to serious health risks. So far, sustainable alternatives to petrochemical film are either too expensive or […]
The global mining industry produces 100 billion tons of waste every year. Often, these waste streams represent environmental hazards, added costs and liabilities for operations, and contain valuable minerals. Athos Bio is developing bio-mineralization technology that mitigates this waste, transforming it into a medium for permanent carbon storage and the recovery of valuable mineral commodities. […]
Every year, 2 million people develop corneal blindness, but only about 200,000 undergo a corneal transplantation to regain their vision. Almost 13 million people are on waiting lists for donor tissue, and even if they obtain it, the rejection rate for corneal replacements climbs from 10% in the first two years to almost 50% by […]
Fashion is among the world’s most wasteful industries. Textile production alone accounts for up to 10% of global carbon emissions – approximately the same as the steel industry. In the U.S., 85% of all clothes are landfilled or incinerated. Synthetic clothing fibers such as polyester and nylon are petrochemicals that can shed microplastics into our […]
Why we invested: At a small networking event, the founders said softly to us: “we are working on a technology that can completely upend the entire sequencing industry.” We leaned in to listen; after all, the founders have been working the front lines during every major pivotal point in sequencing history: Illumina’s acquisition of Solexa […]
Why we invested: The biggest risk in cancer immunotherapy is the safety: the cancer targets (i.e., neoantigens) are not differentiated enough from healthy cells, and can therefore lead to the immune system attacking the patient’s. When we met Dr. Corey Dambacher (the founder of Rybodyn), he said he has been sitting on a treasure trove […]
Why we invested: The world’s biggest meat, produce, and animal health companies take vast sums of money and light it on fire on a recurring basis. They don’t want to do this, but due to consistent shortcoming in pathogen detection no one has managed to avoid the steady recurrence of recall and herd losses. It […]
Why we invested: The message from the market is crystal clear: electric vehicles need to be cheaper. Since up to 40% of an electric vehicle is the battery, and in turn 70% of the cost of the battery is in materials, it’s an imperative for the industry to develop cheaper and higher performing materials. Silicon […]
Why we invested: For all the hype of cell therapies, to get beyond the 5% of eligible patients who receive such therapies today, the market needs 1) higher transfection success, and 2) multi-protein delivery in one construct. The founder of Able sciences are veteran drug developers who invented a self-amplifying RNA that delivers on both […]
California Organic makes the world’s first green ammonia that is California-certified organic. Already in market and growing rapidly, our organic ammonia is made from farm & ag wastes via a bulk fermentation bioprocess. Until today, all organic agriculture has used nitrate fertilizers, which have several inefficiencies. Nitrates are in slurries and so can’t go into […]